Cellectis S.A.(CLLS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,610 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
CLLS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Cellectis S.A. (CLLS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLLS at 26.6/100 on a 32-signal composite quality model, placing it at rank #2,610 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Cellectis S.A. reports quarterly revenue of $72.9M, net income of $-67.6M. Top institutional holders of CLLS by reported 13-F value include B Group, Long Focus Capital Management, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME, based on the most recent SEC filings. CLLS trades on the Nasdaq exchange and files with the SEC under CIK 1627281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cellectis S.A. directly from SEC EDGAR. Cellectis S.A.'s 13F Pro composite quality score has ranged between 27 and 32 since 2026, currently 26.6 — a declining long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue
FY 2025
$72.9M
Net Income
FY 2025
$-67.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+75.8% YoYTotal Assets
-15.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $72.9M +75.8% | $41.5M +5397.4% | $755.0K -96.1% | $19.2M -36.8% | $30.3M -40.6% | $51.1M |
| Total Assets | $324.7M -15.3% | $383.5M +14.7% | $334.3M +28.0% | $261.2M -31.6% | $382.1M -18.6% | $469.5M |
Get alerted when CLLS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cellectis S.A. including:
Top Institutional Holders of CLLS
B Group, Inc.
$9.8M3,281,501 shLong Focus Capital Management, LLC
$8.2M2,741,853 shUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$7.9M2,644,881 shNOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$681.0K226,875 shBlackRock, Inc.
$676.3K225,444 shMORGAN STANLEY
$256.4K85,455 shLPL Financial LLC
$253.2K84,415 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$151.4K50,453 shBNP PARIBAS FINANCIAL MARKETS
$120.3K40,100 shUBS Group AG
$101.8K33,926 sh
| Fund | Value | Shares |
|---|---|---|
| B Group, Inc. | $9.8M | 3,281,501 |
| Long Focus Capital Management, LLC | $8.2M | 2,741,853 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME | $7.9M | 2,644,881 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $681.0K | 226,875 |
| BlackRock, Inc. | $676.3K | 225,444 |
| MORGAN STANLEY | $256.4K | 85,455 |
| LPL Financial LLC | $253.2K | 84,415 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $151.4K | 50,453 |
| BNP PARIBAS FINANCIAL MARKETS | $120.3K | 40,100 |
| UBS Group AG | $101.8K | 33,926 |
Companies Similar to CLLS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Sight Sciences, Inc.
TRINITY BIOTECH PLC
IMMUTEP Ltd
MANNATECH INC
Valneva SE
SINOVAC BIOTECH LTD
Nanobiotix S.A.
Intercure Ltd.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CLLS on your watchlist
Track score changes the day Cellectis S.A. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CLLS a good stock to buy?
13F Pro's AI-powered analysis of Cellectis S.A. (CLLS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLLS are available on the CLLS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CLLS is classified as a small company.
Which hedge funds own CLLS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLLS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cellectis S.A.'s investment landscape.